NanoViricides, Inc. (NNVC)
| Market Cap | 38.95M +76.3% |
| Revenue (ttm) | n/a |
| Net Income | -8.09M |
| EPS | -0.43 |
| Shares Out | 22.78M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 20,819,529 |
| Open | 1.660 |
| Previous Close | 1.510 |
| Day's Range | 1.630 - 1.750 |
| 52-Week Range | 0.850 - 2.230 |
| Beta | 1.54 |
| Analysts | Strong Buy |
| Price Target | 6.00 (+250.88%) |
| Earnings Date | May 15, 2026 |
About NNVC
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company’s product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for NNVC stock is "Strong Buy" and the 12-month stock price target is $6.0.
News
NanoViricides says NV-387 ready to be shipped to DRC for ebola
The company said, “NanoViricides (NNVC) compares potential treatment options for Ebola Bundibugyo virus strain and finds that the Company’s broad-spectrum antiviral drug candidate NV-387 is worthy of ...
In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides
SHELTON, CT / ACCESS Newswire / May 26, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, compares potenti...
NanoViricides Announces Closing of ~$2 Million Registered Direct Offering
SHELTON, CT / ACCESS Newswire / May 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC) ("NanoViricides" or the "Company"), a clinical stage, leading global pioneer in the development of broad-spectru...
NanoViricides emphasizes need for Ebolavirus antiviral drug
NanoViricides (NNVC) emphasizes the need for a broad-spectrum, antiviral drug like NV-387 as another severe Ebolavirus outbreak has occurred in the Eastern part of DR Congo, with spillage across the…
Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides
SHELTON, CT / ACCESS Newswire / May 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, emphasizes the c...
NanoViricides prices $2M registered direct offering
NanoViricides (NNVC) entered into a securities purchase agreement with a single fundamental institutional investor for the purchase and sale of 1,333,334 million common shares, together with accompany...
NanoViricides reports Q1 EPS (9c) vs. (14c) last year
The company said, “We reported that, as of March 31, 2026, we had cash and cash equivalent current assets balance of approximately $3.38 Million. In addition, we reported approximately $10.20…
NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering
SHELTON, CT / ACCESS Newswire / May 15, 2026 / NanoViricides, Inc. (NYSE American:NNVC) ("NanoViricides" or the "Company"), a clinical stage, leading global pioneer in the development of broad-spectru...
NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II
SHELTON, CT / ACCESS Newswire / May 15, 2026 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ending March 31...
NanoViricides says hantavirus incident highlights need for antiviral drugs
NanoViricides (NNVC) emphasizes “the critical need for a revolutionary, broad-spectrum, antiviral drug like NV-387” in light of the recent Andes hantavirus incident on a cruise ship that has led to…
Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides
SHELTON, CT / ACCESS Newswire / May 11, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, emphasizes the c...
NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference
Shelton, Connecticut--(Newsfile Corp. - May 6, 2026) - NanoViricides, Inc. (NYSE American: NNVC), today announced its participation in the D. Boral Capital Global Conference, taking place May 7, 2026,...
NanoViricides announces NV-387 granted ODD by U.S. FDA OOPD
NanoViricides (NNVC) announced that its clinical stage, broad-spectrum, antiviral drug NV-387 has been granted an Orphan Drug Designation, ODD, by the US FDA Office of Orphan Products Development, OOP...
NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA
SHELTON, CT / ACCESS Newswire / May 4, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of br...
NanoViricides measles virus treatment granted FDA orphan status
NanoViricides (NNVC)’ treatment of the measles virus was granted orphan status by the FDA, according to a post to the agency’s website.
NanoViricides says NV-387 can help control spread of measles
NanoViricides (NNVC) comments that its drug candidate NV-387 is the weapon necessary for combatting growing cases of deadly measles worldwide. Bangladesh recently reported 18,219 suspected measles cas...
Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides
SHELTON, CT / ACCESS Newswire / April 21, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of...
NanoViricides files application for RPDD for NV-387 with U.S. OPDD
NanoViricides (NNVC) announced that it has filed an application for “Rare Pediatric Disease Drug” Designation, RPDD, for NV-387 as a Treatment for Measles with the US FDA Office of Orphan…
Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides
SHELTON, CT / ACCESS Newswire / April 7, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of ...
NanoViricides plans to commence Phase II trial of NV-387 for Monkeypox
NanoViricides (NNVC) announced that a Phase II Clinical Trial of Monkeypox Treatment by NV-387 is expected to begin soon in the Democratic Republic of Congo. Clinical Trial Site preparations are…
Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides
SHELTON, CT / ACCESS Newswire / April 1, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today announced that a Phase II Clinical Trial of Monkeypox Treatment by NV-387 is expected to ...
NanoViricides completes manufacture of NV-387 oral gummies
NanoViricides (NNVC) will be presenting at NIBA’s 152nd Investment Conference in Fort Lauderdale, Florida. NanoViricides announces herewith that the manufacture of the drug product for this clinical t...
NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete
SHELTON, CT / ACCESS Newswire / March 11, 2026 / NanoViricides, Inc. (AMEX:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot ...
NanoViricides files application for orphan drug designation for NV-387
NanoViricides (NNVC) filed an application for Orphan Drug Designation for “NV-387 as a Treatment for MPox” with the US FDA Office of Orphan Products Development.
MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides
SHELTON, CONNECTICUT / ACCESS Newswire / February 12, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the de...